A target-agnostic engine for first-in-class drugs
With Grove Biopharma’s proprietary Bionic Biologics™ technology, every protein and protein complex is now in play.
Our breakthrough synthetic chemistry platform enables the design and development of biologics that can permeate cells to drug intracellular protein-protein interaction targets.
Our platform transforms peptides into Bionic Biologics with predictable pharmacology
Bionic Biologics begin with target-binding peptides identified through advanced AI/ML and physics-based computational design, structural biology, antibody CDRs, or phage display technology.
We create modular bionic building blocks with these peptide inputs, then assemble them into protein-scale molecules through a novel precision polymerization process.
This bionic architecture confers unique properties that amplify the function of the peptide inputs. While an individual peptide has a short half-life and cannot penetrate cells, Bionic Biologics are highly stable, potent, and cell permeant, with long half-life. Peptides are transformed into therapeutics that can access intracellular targets.
Bionic Biologics are a novel modality optimal for drug applications
Inherently cell permeable
Dynamic amphiphilicity allows Bionic Biologics to do what other biologics cannot: get into cells to engage PPI targets.
Customizable
Bionic Biologics can be designed as monofunctional or bispecific molecules, to disrupt or degrade protein-protein interactions.
Potent, protein-scale, avidity enhanced intracellular PPI disruptors
Hijacking or mimicking adapter domains or protein degradation machinery
Easy to design
Our platform creates a robust molecular architecture that is modular, for plug-and-play design. Well-defined platform design rules make it simple to create protein-scale molecules that can reach the most complex and formidable targets, such as transcription factors and Ser/Thr phosphatase complexes.
FAQs
Selected Publications
Callman C, et al. "Poly(peptide): Synthesis, Structure, and Function of Peptide-Polymer Amphiphiles and Protein-like Polymers” Acc. Chem. Res. 2020; 53 (2): 400–413. DOI: 10.1021/acs.accounts.9b00518.
Sun H, et al. “Origin of Proteolytic Stability of Peptide-Brush Polymers as Globular Proteomimetics” ACS Cent. Sci. 2021; 7: 2063−2072. DOI:10.1021/acscentsci.1c01149
Oktawiec J, et al. “Conformational modulation and polymerization induced folding of proteomimetic peptide brush polymers” Chem. Sci. 2024; 15: 13899. DOI: 10.1039/D4SC03420A
Choi W, et al. “Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse model” Sci. Adv. 2023; 9 (41). DOI: 10.1126/sciadv.adi8534
